Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06859723 · ClinicalTrials.gov registry record · Phase 1

High Potency Cannabis: Acute and Protracted Effects

A Phase 1 study of Pain and Pharmacokinetics, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06859723 is a Phase 1 study of Pain and Pharmacokinetics that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 30 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06859723, a Phase 1 study of Pain and Pharmacokinetics, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to assess the effects of smoked cananbis when cannabis is smoked during periods of cannabis use as usual and after a brief period of abstinence.

Interventions

  • DRUG Placebo Comparator: Placebo
  • DRUG Low dose THC
  • DRUG High dose THC

Study Locations (1)

California

  • UCLA Center for Cannabis and Cannabinoids - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-07-03
Est. Completion 2028-07-01
Phase Phase 1

What the Registry Record Tells You About NCT06859723

The ClinicalTrials.gov registry entry for NCT06859723 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Placebo Comparator: Placebo is the first listed.

NCT06859723 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06859723 about?

NCT06859723 is a clinical study titled "High Potency Cannabis: Acute and Protracted Effects". The purpose of this research is to assess the effects of smoked cananbis when cannabis is smoked during periods of cannabis use as usual and after a brief period of abstinence.

What is the current status of trial NCT06859723?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-07-03. Estimated completion is 2028-07-01.

What conditions does trial NCT06859723 study?

This clinical trial studies the following conditions: Pain, Pharmacokinetics, Abuse Cannabis.

What interventions are being tested in trial NCT06859723?

The interventions under investigation include: Placebo Comparator: Placebo (DRUG), Low dose THC (DRUG), High dose THC (DRUG).

Who is sponsoring clinical trial NCT06859723?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06859723 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.